Table 2 Clinical characteristics, disease course, complications, and laboratory/imaging findings in NHL patients with persistent vs. non-persistent SARS-CoV-2 infections

Clinical Symptoms

Fever

60 (54.5%)

297 (54.0%)

0.28

Average Temperature (°C)

38.2 ± 0.5

38.1 ± 0.4

0.18

Cough

66 (60.0%)

325 (59.1%)

0.21

Dyspnea

13 (11.8%)

57 (10.4%)

0.18

Oxygen Therapy Required

7 (6.4%)

36 (6.5%)

0.43

Fatigue

34 (30.9%)

161 (29.3%)

0.34

Loss of Smell/Taste

2 (1.8%)

11 (2.0%)

0.09

Disease Course

Average Disease Duration (d)

28.0 ± 12.1

10.0 ± 4.1

< 0.001

Median Disease Duration (d)

32

5

Range of Disease Duration (d)

15–90

3–14

Complications

Myocarditis (n, %)

4 (3.6%)

19 (3.5%)

0.28

Thromboembolism (n, %)

2 (1.8%)

10 (1.8%)

0.13

Acute Kidney Injury (n, %)

2 (1.8%)

9 (1.6%)

0.37

Blood Parameters

White Blood Cell Count (×10⁹/L)

6.2 ± 1.8

5.9 ± 1.6

0.06

D-Dimer (µg/mL)

0.9 ± 0.4

0.8 ± 0.4

0.08

Infection Characteristics

Duration of Persistent Infection (d)

30.2 ± 15.1

5.1 ± 4.1

< 0.01

Viral Load (Mean Ct Value)

34.3 ± 3.5

35.0 ± 3.2

0.41

Duration of Symptoms (d)

11.1 ± 7.1

10.2 ± 6.1

0.32

Recurrence

15 (13.6%)

69 (12.5%)

0.67

Immune Response Indicators

CD4 + T Cell Count (cells/µL)

420.8 ± 200.7

800.4 ± 150.9

< 0.001

IgG Level (g/L)

11.7 ± 2.1

12.5 ± 2.5

0.15

Imaging Findings

Lung Lesions (n, %)

95 (86.4%)

160 (29.1%)

< 0.001

Bilateral Lung Lesions (n, %)

86 (78.2%)

146 (26.5%)

< 0.001

Unilateral Lung Lesion (n, %)

9 (8.2%)

14 (2.5%)

< 0.01